<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02167256</url>
  </required_header>
  <id_info>
    <org_study_id>1404013830</org_study_id>
    <secondary_id>4UH3TR000967-02</secondary_id>
    <nct_id>NCT02167256</nct_id>
  </id_info>
  <brief_title>A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease</brief_title>
  <official_title>A Phase IIa Multi-Center Study of 18F-FDG PET, Safety, and Tolerability of AZD0530 in Mild Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alzheimer's Therapeutic Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      AZD0530 is an inhibitor of Src and Abl family kinases1. It has been developed as treatment
      for malignancies because these kinases play a role in tumor invasion and proliferation.
      However, the Src family kinases (SFKs) are highly expressed in brain and have major effects
      on synaptic plasticity2. Moreover, the investigators have recently shown that a specific SFK,
      namely Fyn, is aberrantly activated by specific conformations of the Amyloid Beta (Aß)
      peptide from Alzheimer's disease (AD). Genetic deletion of Fyn rescues AD deficits in
      preclinical models. This clinical trial will test the potential benefit of AZD0530 for
      Alzheimer's disease modification.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 2014</start_date>
  <completion_date type="Actual">February 27, 2018</completion_date>
  <primary_completion_date type="Actual">February 27, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Brain Glucose Uptake Measured Using 18F-FDG PET Imaging</measure>
    <time_frame>12 months</time_frame>
    <description>Composite measure of brain glucose uptake using F18-FDG PET in a pre-defined set of brain regions, between baseline and 12 months.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With One or More Serious/Other Adverse Events Subjects With Mild AD as Assessed by Analysis of Adverse Events, Including Symptoms, and Abnormal Findings on Physical and Neurological Examinations, and Standard Labs.</measure>
    <time_frame>12 months</time_frame>
    <description>Assessment of any adverse effects between drug and placebo-treated subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Effect of Treatment With AZD0530 on Cognitive and Behavioral Function</measure>
    <time_frame>12 months</time_frame>
    <description>The change in cognitive function between baseline and 12 months will be measured by the following tests:
Alzheimer Disease Assessment Scale - Cognitive 11 (ADAS-cog11). Measures: Cognitive function Maximum score: 70; Minimum score: 0. Higher score equals worse cognitive function
Mini-Mental State Examination (MMSE) Measures: Cognitive Function Maximum score: 30; Minimum score: 0. Higher score equal better cognitive function
Alzheimer Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) Measures: Ability to perform routine daily activities Maximum score: 78; Minimum score: 0. Higher score equals better ability to perform activities of daily living
Clinical Dementia Rating Sum of Boxes (CDR-SO) Measures: Dementia severity Maximum score: 18; Minimum score: 0. Higher score equals more severe dementia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change in Brain Volume Before and After Treatment</measure>
    <time_frame>12 months</time_frame>
    <description>Change in volume of pre-defined brain regions between baseline and 12 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebrospinal Fluid Levels of Total Tau, Phospho-tau (p-Tau), and Amyloid-beta 1-42 (Abeta 1-42)</measure>
    <time_frame>12 months</time_frame>
    <description>Measure concentration of Tau and Amyloid-beta 1-42 biomarkers in the cerebrospinal fluid between baseline and 12 months of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Brain Glucose Uptake Measured Using 18F-FDG PET Imaging</measure>
    <time_frame>12 months</time_frame>
    <description>The results from the primary outcome with brain FDG-PET imaging was analyzed by ApoE genotype. Composite measure of brain glucose uptake using F18-FDG PET in a pre-defined set of brain regions, between baseline and 12 months.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">159</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>AZD0530 100mg daily</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in the experimental group (50%) will be started on this dose. After 2 weeks, patients with a plasma drug level of &lt;100ng/ml will receive 125mg AZD0530 daily and remain in the same experimental group as patient receiving 100mg daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZD0530 Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50% of patients will receive placebo treatment for the duration of the study,</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0530 100mg daily</intervention_name>
    <description>All patients in experimental group (50%) will be started on 100mg AZD0530 daily</description>
    <arm_group_label>AZD0530 100mg daily</arm_group_label>
    <other_name>saracatinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD0530 125mg daily</intervention_name>
    <description>Patients with plasma drug level &lt;100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.</description>
    <arm_group_label>AZD0530 100mg daily</arm_group_label>
    <other_name>saracatinib</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50% of patients will receive placebo treatment for the duration of the study.</description>
    <arm_group_label>AZD0530 Placebo</arm_group_label>
    <other_name>saracatinib</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. NIA-Alzheimer's Association core clinical criteria for probable AD

          2. 18F-Florbetapir scan with evidence of elevated Aβ (based on central review)

          3. Age between 55-85 (inclusive)

          4. MMSE score between 18 and 26 (inclusive)

          5. Stability of permitted medications for 4 weeks. In particular:

               -  Stable doses of antidepressants lacking significant anticholinergic side effects
                  (if they are not currently depressed and do not have a history of major
                  depression within the past 1 year)

               -  Cholinesterase inhibitors and memantine are allowable if stable for 12 weeks
                  prior to screen

          6. Geriatric Depression Scale less than 6 [Note: a score ≥6 on this screening scale may
             be permissible, if the subject is examined by a site clinician and judged not to be
             depressed.]

          7. Study partner is available who has frequent contact with the subject (e.g., average of
             10 hours per week or more), and can accompany the subject to most visits to answer
             questions about the subject

          8. Visual and auditory acuity adequate for neuropsychological testing

          9. Good general health with no disease expected to interfere with the study

         10. Subject is not pregnant, lactating, or of childbearing potential (i.e., women must be
             two years post-menopausal or surgically sterile)

         11. Modified Hachinski less than or equal to 4

         12. Completed six grades of education or has a good work history

         13. Must speak English or Spanish fluently

        Exclusion Criteria

          1. Any significant neurologic disease other than AD, such as Parkinson's disease,
             multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, brain
             tumor, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple
             sclerosis, or history of significant head trauma followed by persistent neurologic
             defaults or known structural brain abnormalities

          2. Screening/baseline MRI scan with evidence of infection, infarction, or other focal
             lesions or multiple lacunes or lacunes in a critical memory structure

          3. Subjects that have any contraindications for MRI studies, including claustrophobia,
             the presence of metal (ferromagnetic) implants, or cardiac pacemaker

          4. Major depression, bipolar disorder as described in DSM-IV within the past 1 year or
             psychotic features, agitation or behavioral problems within 3 months, which could lead
             to difficulty complying with the protocol

          5. History of schizophrenia (DSM V criteria)

          6. History of alcohol or substance abuse or dependence within the past 2 years (DSM V
             criteria)

          7. Clinically significant or unstable medical condition, including uncontrolled
             hypertension, uncontrolled diabetes, or significant cardiac, pulmonary, renal,
             hepatic, endocrine, or other systemic disease in the opinion of the Investigator, may
             either put the subject at risk because of participation in the study, or influence the
             results, or the subject's ability to participate in the study.

          8. Has had a history within the last 5 years of a primary or recurrent malignant disease
             with the exception of non-melanoma skin cancers, resected cutaneous squamous cell
             carcinoma in situ, basal cell carcinoma, cervical carcinoma in situ, or in situ
             prostate cancer with normal prostate-specific antigen post-treatment

          9. Clinically significant abnormalities in B12 or TFTs that might interfere with the
             study. A low B12 is exclusionary, unless follow-up labs (homocysteine (HC) and
             methylmalonic acid (MMA)) indicate that it is not physiologically significant.

         10. Residence in skilled nursing facility.

         11. Use of any excluded medication as described in study protocol

         12. Current or recent participation in any procedures involving radioactive agents,
             including current, past, or anticipated exposure to radiation in the workplace, such
             that the total radiation dose exposure to the subject in a given year would exceed the
             limits of annual and total dose commitment set forth in the US Code of Federal
             Regulations (CFR) Title 21 Section 361.1. This guideline is an effective dose of 5 rem
             received per year.

         13. Neutropenia defined as absolute neutrophils count of &lt;1,800/microliter

         14. Thrombocytopenia defined as platelet count &lt;120x103/microliter

         15. For CSF sub-study participants, a current blood clotting or bleeding disorder, or
             significantly abnormal PT or PTT at screening

         16. Clinically significant abnormalities in screening laboratories, including:

               -  Aspartate aminotransferase (AST) &gt;1.5 times ULN

               -  Alanine aminotransferase (ALT) &gt; 1.5 times ULN

               -  Total bilirubin &gt;1.5 times ULN

               -  Serum creatinine &gt;2.0 times ULN

         17. History of interstitial lung disease

         18. Patients whom the PI deems to be otherwise ineligible
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher H van Dyck, MD</last_name>
    <role>Study Director</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Aisen, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>USC Alzheimer's Therapeutic Research Institute (ATRI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barrow Neurological Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85013</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Banner Sun Health Research Institute</name>
      <address>
        <city>Sun City</city>
        <state>Arizona</state>
        <zip>85351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale Alzheimer's Disease Research Unit</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wien Center for Clinical Research/Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Florida - Health Byrd Alzheimer Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan, Ann Arbor</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105-2945</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh, Alzheimer's Disease Research Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roper St. Francis Hospital</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia, Clinic for AD &amp; Related Disorders</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 1Z3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>June 12, 2014</study_first_submitted>
  <study_first_submitted_qc>June 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2014</study_first_posted>
  <results_first_submitted>June 19, 2019</results_first_submitted>
  <results_first_submitted_qc>July 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 14, 2019</results_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Stephen M. Strittmatter</investigator_full_name>
    <investigator_title>Professor of Neurology and Neurobiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Saracatinib</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/56/NCT02167256/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AZD0530 100mg/125mg Daily</title>
          <description>AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily
AZD0530 125mg daily: Patients with plasma drug level &lt;100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530.</description>
        </group>
        <group group_id="P2">
          <title>AZD0530 Placebo</title>
          <description>Placebo: 50% of patients will receive placebo treatment for the duration of the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="80"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study partner unable to participate</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD0530 100mg Daily</title>
          <description>Patients in the experimental group (50%) will be started on this dose. After 2 weeks, patients with a plasma drug level of &lt;100ng/ml will receive 125mg AZD0530 daily and remain in the same experimental group as patient receiving 100mg daily.
AZD0530 100mg daily: All patients in experimental group (50%) will be started on 100mg AZD0530 daily
AZD0530 125mg daily: Patients with plasma drug level &lt;100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.</description>
        </group>
        <group group_id="B2">
          <title>AZD0530 Placebo</title>
          <description>50% of patients will receive placebo treatment for the duration of the study,
Placebo: 50% of patients will receive placebo treatment for the duration of the study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="79"/>
            <count group_id="B2" value="80"/>
            <count group_id="B3" value="159"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="49"/>
                    <measurement group_id="B3" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>White (not Hispanic)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74"/>
                    <measurement group_id="B2" value="68"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaskan Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="76"/>
                    <measurement group_id="B2" value="76"/>
                    <measurement group_id="B3" value="152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Brain Glucose Uptake Measured Using 18F-FDG PET Imaging</title>
        <description>Composite measure of brain glucose uptake using F18-FDG PET in a pre-defined set of brain regions, between baseline and 12 months.</description>
        <time_frame>12 months</time_frame>
        <population>Number of participants is lower than total randomized participants due to a modified intent-to-treat analysis where only randomized participants who also underwent a post-baseline F18-FDG PET brain scan are included.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD0530 100mg/125mg Daily</title>
            <description>AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily
AZD0530 125mg daily: Patients with plasma drug level &lt;100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530.</description>
          </group>
          <group group_id="O2">
            <title>AZD0530 Placebo</title>
            <description>Placebo: 50% of patients will receive placebo treatment for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Brain Glucose Uptake Measured Using 18F-FDG PET Imaging</title>
          <description>Composite measure of brain glucose uptake using F18-FDG PET in a pre-defined set of brain regions, between baseline and 12 months.</description>
          <population>Number of participants is lower than total randomized participants due to a modified intent-to-treat analysis where only randomized participants who also underwent a post-baseline F18-FDG PET brain scan are included.</population>
          <units>umol/100g/min (change)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.03"/>
                    <measurement group_id="O2" value="-0.05" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With One or More Serious/Other Adverse Events Subjects With Mild AD as Assessed by Analysis of Adverse Events, Including Symptoms, and Abnormal Findings on Physical and Neurological Examinations, and Standard Labs.</title>
        <description>Assessment of any adverse effects between drug and placebo-treated subjects</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0530 100mg/125mg Daily</title>
            <description>AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily
AZD0530 125mg daily: Patients with plasma drug level &lt;100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530.</description>
          </group>
          <group group_id="O2">
            <title>AZD0530 Placebo</title>
            <description>Placebo: 50% of patients will receive placebo treatment for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With One or More Serious/Other Adverse Events Subjects With Mild AD as Assessed by Analysis of Adverse Events, Including Symptoms, and Abnormal Findings on Physical and Neurological Examinations, and Standard Labs.</title>
          <description>Assessment of any adverse effects between drug and placebo-treated subjects</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Subjects with one or more adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                    <measurement group_id="O2" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subjects with one or more serious adverse events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Effect of Treatment With AZD0530 on Cognitive and Behavioral Function</title>
        <description>The change in cognitive function between baseline and 12 months will be measured by the following tests:
Alzheimer Disease Assessment Scale - Cognitive 11 (ADAS-cog11). Measures: Cognitive function Maximum score: 70; Minimum score: 0. Higher score equals worse cognitive function
Mini-Mental State Examination (MMSE) Measures: Cognitive Function Maximum score: 30; Minimum score: 0. Higher score equal better cognitive function
Alzheimer Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) Measures: Ability to perform routine daily activities Maximum score: 78; Minimum score: 0. Higher score equals better ability to perform activities of daily living
Clinical Dementia Rating Sum of Boxes (CDR-SO) Measures: Dementia severity Maximum score: 18; Minimum score: 0. Higher score equals more severe dementia.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0530 100mg/125mg Daily</title>
            <description>AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily
AZD0530 125mg daily: Patients with plasma drug level &lt;100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530.</description>
          </group>
          <group group_id="O2">
            <title>AZD0530 Placebo</title>
            <description>Placebo: 50% of patients will receive placebo treatment for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>The Effect of Treatment With AZD0530 on Cognitive and Behavioral Function</title>
          <description>The change in cognitive function between baseline and 12 months will be measured by the following tests:
Alzheimer Disease Assessment Scale - Cognitive 11 (ADAS-cog11). Measures: Cognitive function Maximum score: 70; Minimum score: 0. Higher score equals worse cognitive function
Mini-Mental State Examination (MMSE) Measures: Cognitive Function Maximum score: 30; Minimum score: 0. Higher score equal better cognitive function
Alzheimer Disease Cooperative Study - Activities of Daily Living Inventory (ADCS-ADL) Measures: Ability to perform routine daily activities Maximum score: 78; Minimum score: 0. Higher score equals better ability to perform activities of daily living
Clinical Dementia Rating Sum of Boxes (CDR-SO) Measures: Dementia severity Maximum score: 18; Minimum score: 0. Higher score equals more severe dementia.</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="79"/>
                <count group_id="O2" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ADAS-Cog score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.26" spread="0.954"/>
                    <measurement group_id="O2" value="6.14" spread="0.903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MMSE score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.84" spread="0.575"/>
                    <measurement group_id="O2" value="-3.33" spread="0.543"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADCS-ADL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.49" spread="1.263"/>
                    <measurement group_id="O2" value="-7.64" spread="1.199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CDR-SO</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.946" spread="0.292"/>
                    <measurement group_id="O2" value="1.468" spread="0.274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change in Brain Volume Before and After Treatment</title>
        <description>Change in volume of pre-defined brain regions between baseline and 12 months of treatment.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD0530 100mg/125mg Daily</title>
            <description>AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily
AZD0530 125mg daily: Patients with plasma drug level &lt;100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530.</description>
          </group>
          <group group_id="O2">
            <title>AZD0530 Placebo</title>
            <description>Placebo: 50% of patients will receive placebo treatment for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Brain Volume Before and After Treatment</title>
          <description>Change in volume of pre-defined brain regions between baseline and 12 months of treatment.</description>
          <units>% change in volume</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Entorhinal volume change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3939" spread="1.8138"/>
                    <measurement group_id="O2" value="-3.1002" spread="1.7446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Whole brain volume change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.5993" spread="1.0569"/>
                    <measurement group_id="O2" value="-1.7077" spread="1.0922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hippocampus volume change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.8931" spread="1.8089"/>
                    <measurement group_id="O2" value="-1.542" spread="1.9893"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cerebrospinal Fluid Levels of Total Tau, Phospho-tau (p-Tau), and Amyloid-beta 1-42 (Abeta 1-42)</title>
        <description>Measure concentration of Tau and Amyloid-beta 1-42 biomarkers in the cerebrospinal fluid between baseline and 12 months of treatment</description>
        <time_frame>12 months</time_frame>
        <population>Number of participants is lower than total randomized participants due to a modified intent-to-treat analysis where only randomized participants who also underwent a post-baseline cerebrospinal fluid analysis were included.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD0530 100mg/125mg Daily</title>
            <description>AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily
AZD0530 125mg daily: Patients with plasma drug level &lt;100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530.</description>
          </group>
          <group group_id="O2">
            <title>AZD0530 Placebo</title>
            <description>Placebo: 50% of patients will receive placebo treatment for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Cerebrospinal Fluid Levels of Total Tau, Phospho-tau (p-Tau), and Amyloid-beta 1-42 (Abeta 1-42)</title>
          <description>Measure concentration of Tau and Amyloid-beta 1-42 biomarkers in the cerebrospinal fluid between baseline and 12 months of treatment</description>
          <population>Number of participants is lower than total randomized participants due to a modified intent-to-treat analysis where only randomized participants who also underwent a post-baseline cerebrospinal fluid analysis were included.</population>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CSF Total tau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.7448" spread="212.7244"/>
                    <measurement group_id="O2" value="1.2091" spread="131.2533"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSF p-Tau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5837" spread="17.7504"/>
                    <measurement group_id="O2" value="-1.9986" spread="13.7311"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSF Abeta 1-42</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3383" spread="47.3549"/>
                    <measurement group_id="O2" value="-1.3758" spread="43.3233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Brain Glucose Uptake Measured Using 18F-FDG PET Imaging</title>
        <description>The results from the primary outcome with brain FDG-PET imaging was analyzed by ApoE genotype. Composite measure of brain glucose uptake using F18-FDG PET in a pre-defined set of brain regions, between baseline and 12 months.</description>
        <time_frame>12 months</time_frame>
        <population>Number of participants is lower than total randomized participants due to a modified intent-to-treat analysis where only randomized participants who also underwent a post-baseline F18-FDG PET brain scan are included.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD0530 100mg/125mg Daily</title>
            <description>AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily
AZD0530 125mg daily: Patients with plasma drug level &lt;100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530.</description>
          </group>
          <group group_id="O2">
            <title>AZD0530 Placebo</title>
            <description>Placebo: 50% of patients will receive placebo treatment for the duration of the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Brain Glucose Uptake Measured Using 18F-FDG PET Imaging</title>
          <description>The results from the primary outcome with brain FDG-PET imaging was analyzed by ApoE genotype. Composite measure of brain glucose uptake using F18-FDG PET in a pre-defined set of brain regions, between baseline and 12 months.</description>
          <population>Number of participants is lower than total randomized participants due to a modified intent-to-treat analysis where only randomized participants who also underwent a post-baseline F18-FDG PET brain scan are included.</population>
          <units>umol/100g/min (change)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="72"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>APOE4 carrier FDG-PET measure from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.03"/>
                    <measurement group_id="O2" value="-0.05" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>APOE4 non-carrier FDG-PET measure from baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" spread="0.03"/>
                    <measurement group_id="O2" value="-0.05" spread="0.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events data were collected over a period of 1 year (study duration)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>AZD0530 100mg/125mg Daily</title>
          <description>AZD0530 100mg daily: All patients in experimental group (50%) were started on 100mg AZD0530 daily
AZD0530 125mg daily: Patients with plasma drug level &lt;100ng/ml after 2 weeks of 100mg AZD0530 daily received 125mg daily of AZD0530.</description>
        </group>
        <group group_id="E2">
          <title>AZD0530 Placebo</title>
          <description>Placebo: 50% of patients will receive placebo treatment for the duration of the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="65" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Blood and lymphatic system disorders</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear and labyrinth disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye disorders</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General disorders and administration site conditions</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Immune system disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infections and infestations</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Injury, poisoning and procedural complications</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Investigations</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Metabolism and nutrition disorders</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="24" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Nervous system disorders</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric disorders</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal and urinary disorders</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin and subcutaneous tissue disorders</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Vascular disorders</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="79"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="80"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stephen Strittmatter</name_or_title>
      <organization>Yale University</organization>
      <phone>2037854878</phone>
      <email>stephen.strittmatter@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

